Treatment of Parkinson's disease: a survey of patients and neurologists.
Identifieur interne : 000E13 ( PubMed/Corpus ); précédent : 000E12; suivant : 000E14Treatment of Parkinson's disease: a survey of patients and neurologists.
Auteurs : Matthias Fargel ; Bernd Grobe ; Eberhard Oesterle ; Claudia Hastedt ; Markus RuppSource :
- Clinical drug investigation [ 1173-2563 ] ; 2007.
English descriptors
- KwdEn :
- Antiparkinson Agents (classification), Antiparkinson Agents (therapeutic use), Drug Therapy, Combination, Drug Utilization Review (methods), Drug Utilization Review (statistics & numerical data), Europe, Female, Health Care Surveys, Humans, Interviews as Topic (methods), Male, Neurology (statistics & numerical data), Parkinson Disease (drug therapy), Parkinson Disease (pathology), Patient Education as Topic (methods), Patient Education as Topic (statistics & numerical data), Patient Satisfaction (statistics & numerical data), Patients (statistics & numerical data), Practice Guidelines as Topic, Severity of Illness Index, Surveys and Questionnaires, Treatment Outcome, United States.
- MESH :
- chemical , classification : Antiparkinson Agents.
- chemical , therapeutic use : Antiparkinson Agents.
- geographic : Europe, United States.
- drug therapy : Parkinson Disease.
- methods : Drug Utilization Review, Interviews as Topic, Patient Education as Topic.
- pathology : Parkinson Disease.
- statistics & numerical data : Drug Utilization Review, Neurology, Patient Education as Topic, Patient Satisfaction, Patients.
- Drug Therapy, Combination, Female, Health Care Surveys, Humans, Male, Practice Guidelines as Topic, Severity of Illness Index, Surveys and Questionnaires, Treatment Outcome.
Abstract
The treatment of Parkinson's disease (PD) is complex and highly individual. The choice between available treatment options depends on clinical characteristics such as the patient's age, disease severity and presence of comorbidities, lifestyle characteristics and preferences, costs of different medications and awareness and perception of available treatment options, and education of the treating physician. The impact of PD treatment regimens on patients' health-related quality of life (QOL) is also an important healthcare feature. The objective of the present study was to assess treatment options, treatment satisfaction and opinions about treatment improvements in patients with PD and neurologists treating the disease.
PubMed: 17305415
Links to Exploration step
pubmed:17305415Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of Parkinson's disease: a survey of patients and neurologists.</title><author><name sortKey="Fargel, Matthias" sort="Fargel, Matthias" uniqKey="Fargel M" first="Matthias" last="Fargel">Matthias Fargel</name><affiliation><nlm:affiliation>Psyma International Medical Marketing Research GmbH, Rückersdorf, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Grobe, Bernd" sort="Grobe, Bernd" uniqKey="Grobe B" first="Bernd" last="Grobe">Bernd Grobe</name></author><author><name sortKey="Oesterle, Eberhard" sort="Oesterle, Eberhard" uniqKey="Oesterle E" first="Eberhard" last="Oesterle">Eberhard Oesterle</name></author><author><name sortKey="Hastedt, Claudia" sort="Hastedt, Claudia" uniqKey="Hastedt C" first="Claudia" last="Hastedt">Claudia Hastedt</name></author><author><name sortKey="Rupp, Markus" sort="Rupp, Markus" uniqKey="Rupp M" first="Markus" last="Rupp">Markus Rupp</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17305415</idno><idno type="pmid">17305415</idno><idno type="wicri:Area/PubMed/Corpus">000E13</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E13</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment of Parkinson's disease: a survey of patients and neurologists.</title><author><name sortKey="Fargel, Matthias" sort="Fargel, Matthias" uniqKey="Fargel M" first="Matthias" last="Fargel">Matthias Fargel</name><affiliation><nlm:affiliation>Psyma International Medical Marketing Research GmbH, Rückersdorf, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Grobe, Bernd" sort="Grobe, Bernd" uniqKey="Grobe B" first="Bernd" last="Grobe">Bernd Grobe</name></author><author><name sortKey="Oesterle, Eberhard" sort="Oesterle, Eberhard" uniqKey="Oesterle E" first="Eberhard" last="Oesterle">Eberhard Oesterle</name></author><author><name sortKey="Hastedt, Claudia" sort="Hastedt, Claudia" uniqKey="Hastedt C" first="Claudia" last="Hastedt">Claudia Hastedt</name></author><author><name sortKey="Rupp, Markus" sort="Rupp, Markus" uniqKey="Rupp M" first="Markus" last="Rupp">Markus Rupp</name></author></analytic><series><title level="j">Clinical drug investigation</title><idno type="ISSN">1173-2563</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (classification)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Drug Utilization Review (methods)</term><term>Drug Utilization Review (statistics & numerical data)</term><term>Europe</term><term>Female</term><term>Health Care Surveys</term><term>Humans</term><term>Interviews as Topic (methods)</term><term>Male</term><term>Neurology (statistics & numerical data)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (pathology)</term><term>Patient Education as Topic (methods)</term><term>Patient Education as Topic (statistics & numerical data)</term><term>Patient Satisfaction (statistics & numerical data)</term><term>Patients (statistics & numerical data)</term><term>Practice Guidelines as Topic</term><term>Severity of Illness Index</term><term>Surveys and Questionnaires</term><term>Treatment Outcome</term><term>United States</term></keywords><keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Europe</term><term>United States</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Utilization Review</term><term>Interviews as Topic</term><term>Patient Education as Topic</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Drug Utilization Review</term><term>Neurology</term><term>Patient Education as Topic</term><term>Patient Satisfaction</term><term>Patients</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Therapy, Combination</term><term>Female</term><term>Health Care Surveys</term><term>Humans</term><term>Male</term><term>Practice Guidelines as Topic</term><term>Severity of Illness Index</term><term>Surveys and Questionnaires</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The treatment of Parkinson's disease (PD) is complex and highly individual. The choice between available treatment options depends on clinical characteristics such as the patient's age, disease severity and presence of comorbidities, lifestyle characteristics and preferences, costs of different medications and awareness and perception of available treatment options, and education of the treating physician. The impact of PD treatment regimens on patients' health-related quality of life (QOL) is also an important healthcare feature. The objective of the present study was to assess treatment options, treatment satisfaction and opinions about treatment improvements in patients with PD and neurologists treating the disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17305415</PMID><DateCreated><Year>2007</Year><Month>02</Month><Day>19</Day></DateCreated><DateCompleted><Year>2007</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1173-2563</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>3</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Clinical drug investigation</Title><ISOAbbreviation>Clin Drug Investig</ISOAbbreviation></Journal><ArticleTitle>Treatment of Parkinson's disease: a survey of patients and neurologists.</ArticleTitle><Pagination><MedlinePgn>207-18</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The treatment of Parkinson's disease (PD) is complex and highly individual. The choice between available treatment options depends on clinical characteristics such as the patient's age, disease severity and presence of comorbidities, lifestyle characteristics and preferences, costs of different medications and awareness and perception of available treatment options, and education of the treating physician. The impact of PD treatment regimens on patients' health-related quality of life (QOL) is also an important healthcare feature. The objective of the present study was to assess treatment options, treatment satisfaction and opinions about treatment improvements in patients with PD and neurologists treating the disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Two surveys using face-to-face interviews and an additional phone survey were carried out in the US and five European countries (France, Germany, Italy, Spain and the UK). Patients with early and advanced stages of PD were included. To participate in the neurologist survey, neurologists were required to personally treat ten or more PD patients per month, including both early and advanced stage patients. Interviews consisted of a mix of closed and open-ended questions; some of these questions involved show cards.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 500 patients who were surveyed, 49% had early and 51% had advanced PD. Early-stage PD patients, both in the US and Europe, take a mean of 3.2 tablets daily of PD-medication. In contrast, the mean daily tablet load of PD medication is much higher for advanced-stage patients (9.9 and 8.4 tablets in the US and Europe, respectively). Tablet load was perceived as a major problem; the majority of patients wished to see improvements regarding daily medication intake and expressed interest in other delivery systems such as patches. Overall, patients rated their treatment with a score of 6.6 points (6.7 for early-stage and 6.6 for advanced-stage patients) [scale of 1-10; 10 being highest]. Physicians (n = 592) were satisfied with a number of current PD medications and assumed they improve the QOL of the patients. They regarded efficacy and safety as the most important features for the improvement of PD medication.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Further research is needed into PD treatment options not only for symptom alleviation but for better delivery systems that could improve compliance and QOL for patients with PD. Treatment guidelines need to incorporate QOL aspects and general communication between the health professional and the patient.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fargel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Psyma International Medical Marketing Research GmbH, Rückersdorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grobe</LastName><ForeName>Bernd</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Oesterle</LastName><ForeName>Eberhard</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Hastedt</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rupp</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Clin Drug Investig</MedlineTA><NlmUniqueID>9504817</NlmUniqueID><ISSNLinking>1173-2563</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017723" MajorTopicYN="N">Drug Utilization Review</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019538" MajorTopicYN="N">Health Care Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007407" MajorTopicYN="N">Interviews as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009462" MajorTopicYN="N">Neurology</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010361" MajorTopicYN="N">Patients</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17305415</ArticleId><ArticleId IdType="pii">2734</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E13 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000E13 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:17305415
|texte= Treatment of Parkinson's disease: a survey of patients and neurologists.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17305415" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |